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Abstract
Background: This study aims to evaluate: 1) the prevalence of Female Sexual Dysfunction (FSD) in women affected
by type 1 Diabetes Mellitus (DM) and the control group; 2) the correlation between duration of DM, HbA1C levels
and sexual life quality; 3) the relationship between different methods of insulin administration and sexual life
quality; 4) the correlation between FSD and diabetes complications.
Methods: We selected 33 women with type 1 DM and 39 healthy women as controls. Each participant underwent
a detailed medical history and physical examination and completed the 6-item Female Sexual Function Index
questionnaire (FSFI-6). In patients affected by type 1 DM, the different methods of insulin administration (Multi Drug
Injection - MDI or Continuous Subcutaneous Insulin Infusion - CSII) and the presence of DM complications were
also investigated.
Results: The prevalence of FSD (total score ≤ 19) was significantly higher in the type 1 DM group than in the
control group (12/33, 36.4% and 2/39, 5.2%, respectively; p = 0.010). No statistically significant differences were
found regarding FSD according to the presence of complications, method of insulin administration or previous
pregnancies.
Conclusions: This study underlined that FSD is higher in women affected by type 1 DM than in healthy controls.
This could be due to the diabetic neuropathy/angiopathy and the type of insulin administration. Therefore, it is
important to investigate FSD in diabetic women, as well as erectile dysfunction in diabetic men.
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Background
Female Sexual Dysfunction (FSD) is an heterogeneous
group of disorders characterized by clinically significant
disturbances in sexual response or the experience of sex-
ual pleasure. The physiology of female sexual response
includes the integrity of the vascular system and of the
sensory and autonomic nervous system. Furthermore, a
negative association between dissatisfaction with male
partner’s sexual performance and female sexual func-
tioning could exist [1].
Many possible organic factors potentially associated with
FSD have been studied so far. Although still limited, cur-
rently available data show a correlation between FSD and
dysmetabolic conditions such as diabetes mellitus (DM),
dyslipidaemia, metabolic syndrome and obesity [2–4].
The impact of DM on the pathophysiology of male sex-
ual dysfunction has been already widely investigated [5].
In the latest guidelines for DM treatment [6], male sexual
dysfunction is mentioned among diabetes complications,
yet there is no mention of female sexual dysfunction. FSD,
due to both complexity and socio-cultural reasons, has
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been studied with a certain delay compared to male sexual
dysfunction.
Diabetes is associated with tissue hypotrophy and sensi-
tivity impairment, as a consequence of the synergetic effects
of vasculopathy and neuropathy [7, 8]. Interestingly, a
positive association between clitoral vascular resistance
(assessed by clitoral ecocolorDoppler ultrasound) and
metabolic syndrome (mainly insulin resistance) with de-
creased sexual arousal, body image concerns, and increased
somatised anxiety symptoms was also reported [9].
There are few and discordant data on the prevalence of
FSD in diabetic women due to differences in methodology
(face-to-face interviews, mail questionnaires, telephone in-
terviews), sample size definition and classification of sever-
ity of the disease. The prevalence of type 1 diabetes in
Italy is equal to 0.3%; 50.4% of women with type 1 diabetes
are of childbearing age (15–45 years) [10].
According to a previous study by Enzlin et al., the
prevalence of FSD in women with diabetes is about 30%
[11]. Regarding the aetiology, the same study highlights
both somatic and psychological components as possible
risk factors of FSD, even though psychological factors
seem to be prevalent.
Another Italian study, conducted on 595 diabetic
women aged between 35 and 70, showed an FSD preva-
lence of 54%, reaching 64% during menopause [3]. Ac-
cording to an Italian meta-analysis, FSD is more common
in diabetic women than in healthy controls; the odds ratio
of FSD is 2.27 in type 1 DM and 2.49 in type 2 diabetes,
while it is 2.02 when considering diabetes in general [12].
Therefore, DM could determine a significantly nega-
tive impact on female sexual function, especially when
associated with other risk factors, and could signifi-
cantly affect quality of life (QoL) and interpersonal
relationships [13].
The current work aims to evaluate: 1) the prevalence
of Female Sexual Dysfunction (FSD) in women affected
by type 1 Diabetes Mellitus (DM) and the control group;
2) the correlation between duration of DM, HbA1C
levels and sexual life quality; 3) the relationship between
different methods of insulin administration and sexual
life quality; 4) the correlation between FSD and diabetes
complications.
Methods
Participants
In the present pilot case-control study, we enrolled 72
women from January 2016 to May 2017. Of these, 33
women with type 1 diabetes attended our outpatient
clinic (Endocrinology and Diabetology Unit, Sant’Andrea
Hospital) for a regular diabetes check, whilst the other
39 healthy control women were recruited from the ad-
ministrative and clinical staff of the Hospital. The med-
ical staff informed all participants about the existence of
this study; participants voluntarily accepted to partici-
pate in the study and all signed informed consent.
All participants met the following inclusion criteria:
age 18–45 years; premenopausal status and no menstrual
abnormalities; no concomitant pathologies (excluding
diabetes complications); no use of other medications (a
part of insulin); sexual activity over the last 4 weeks; het-
erosexual orientation; a stable relationship for at least 1
year; absence of sexual disorders in the male partners;
and an interval of at least 1 year from the last pregnancy.
All controls reported to be healthy, not to take any
pharmacological treatment and without a history of dia-
betes or gestational diabetes.
All subjects enrolled in the present study underwent a
detailed medical history collection and a physical examin-
ation including Body Mass Index (BMI Kg/m2) calcula-
tion; mean age and former pregnancies were considered.
In addition, in patients affected by type 1 DM, the fol-
lowing aspects were considered: a) time of onset and
duration of type 1 DM, as well as HbA1C values; b)
treatment of DM (i.e. Multi Drug Injection - MDI or
Continuous Subcutaneous Insulin Infusion - CSII); and
c) the study of DM complications through cardiologic,
nephrologic, neurologic and ophthalmologic evaluations.
Questionnaire
The Italian Female Sexual Function Index-6 (FSFI-6)
questionnaire [14, 15] is a validated and reliable short
form questionnaire to identify symptoms of sexual dys-
function, with an optimal ability in discriminating FSD,
with a 93% sensibility and a 94% specificity. It includes
six domains: desire, arousal, lubrication, orgasm, satis-
faction and dyspareunia. Each subscale is scored from 0
or 1 (worst possible sexual outcome) to 5 (best possible
sexual outcome). The total score ranges from 3 to 30. As
suggested by Isidori et al., a total score ≤ 19 was consid-
ered to be indicative of sexual dysfunction [16].
The FSFI-6 was self-administered and fulfilled inde-
pendently by each participant in a dedicated hospital
room without any possible influence and/or interference
from physicians or other healthcare professionals. A
sexological counselling was offered to women with a
FSFI-6 total score ≤ 19.
Data analysis
The mean and standard deviation (SD) was calculated
for all measured variables. The Kolmogorov-Smirnov
test was used to assess the normality of distribution. Un-
paired t tests, Mann-Whitney tests and Fisher exact tests
were used to analyse differences in personal and demo-
graphic data, as appropriate.
Mann-Whitney tests were used to detect statistical dif-
ferences between the FSFI-scores of the experimental
and the control group. Comparisons of CSII-treated
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women, MDI-treated women and controls were car-
ried out through Kruskal Wallis tests and post hoc
Dunn tests.
Similarly, comparisons between diabetic women with-
out complications, diabetic women with at least one
complication and controls were carried out using the
Kruskal Wallis and post hoc Dunn tests. The differences
in FSD prevalence (referred to as a total FSFI-6 score ≤
19) were investigated by Fisher’s exact tests.
A Spearman correlation test was carried out between
the total scores of the FSFI-6 questionnaire and BMIs of
the entire sample. Finally, a logistic regression analysis
was performed using FSD as dependent variable, and
BMI and diabetes as two different predictors.
A p value of 0.05 was considered for the statistical
procedures. Statistical analysis was carried out with
GraphPadInStat software (Version 3.06 for Windows,
San Diego, CA, USA).
Sample-size calculation
On the basis of our previous observations [17], we as-
sumed a female sexual dysfunction rate equal to 51% in
diabetic women and 9% in controls; therefore, the recruit-
ment of 34 participants would be required to achieve 80%
power, with an estimated α error, 0.05 and β error, 0.2.
Statistical analysis was carried out with clincalc.com.
Results
No significant differences were found among the main
basal characteristics regarding patients with type1 DM
and control group (Table 1).
Questionnaires
The results are summarised in Table 2.
The prevalence of FSD (total score ≤ 19) was signifi-
cantly higher in the type 1 DM group (12/33, 36.4%;
95% confidence interval [CI] 18–31) compared to the
control group (2/39, 5.2%; 95% CI 3–5; p = 0.010). The
Relative Risk (RR) was 2.4.
Total score was significantly lower in type1 DM com-
pared to the control group (p < 0.0001).
Regarding the single items, a significant difference was
found for item 1, 2, 3 and 4 (p < 0.0001, p = 0.0156, p =
0.0017 and p = 0.0119, respectively).
BMI
The mean values of BMI in the group of women affected by
type 1 DM was significantly higher compared to the control
group (25.1 ± 5.0 vs. 20.9 ± 3.0; p < 0.0001) (Table 1).
A significant correlation was found between BMI
values and FSFI-6 total scores in the whole population
(Spearman correlation analysis; p = 0.0029).
However, when we divided diabetic patients into three
sub-groups according to BMI values kg/m2 (BMI < 25
(21.8 ± 2.5), n.19; BMI ≥25 < 30 (27.4 ± 1.5), n.10; BMI ≥
30, (34.4 ± 4.8), n.4), no significant difference was ob-
served in FSFI-6 mean total scores (FSFI total scores:
BMI < 25: 19.9 ± 5.6 vs BMI 25–30: 20.3 ± 4.8 vs BMI >
30: 22.0 ± 6.9, respectively; ANOVA: p = n.s).
When a logistic regression analysis was performed using
FSD as dependent variable and BMI and diabetes as differ-
ent predictors, only diabetes remained significant (dia-
betes, p = 0.015; RR 2,4 95% C.I 15.6–3.5; BMI, P = 0.32).
Previous pregnancies
The prevalence of uniparous or multiparous women was
higher among women with type 1 DM (25/33; 75.8%)
compared to the control group (11/39; 28.0%) (p =
0.0001). Nonetheless, a comparison between uniparous/
multiparous women and nulliparous women of the type
1 DM group showed no significant differences for any of
the FSFI-6 items or total score (Table 3a). Similar results
were obtained when comparing uniparous/multiparous
women and nulliparous women from the control group
(Table 3b).
Onset and duration of DM, HbA1c
The results are summarised in Table 4.
Table 1 Basal characteristics of Type 1 DM group and Control group
Type 1 DM (n.33) Control group (n.39) P value
Age (years; mean ± SD, range) 38.7 ± 5.1 (27–44) 37.6 ± 4.3 (27–44) 0.3355
Menarche (years; mean ± SD, range) 12.4 ± 1.6 (10–16) 12.7 ± 1.2 (11–15) 0.5323
Marital status (n.; %) 20/33 (60.6%) 25/39 (64.1%) 0.8102
High education level (University, Specialization, Master, PhD) (n.; %) 10/33 (30.3%) 11/39 (28.2%) 1.000
Smoking habits (n.; %) 7/33 (21.2%) 13/39 (33.3%) 0.2988
Alcohol consumers (n.; %) 10 /33 (30.3%) 12/39 (30.8%) 1.000
Physical activity (n.; %) 14/33 (42.4%) 19/39 (48.7%) 0.6407
BMI (Kg/m2; mean ± SD, range) 25.1 ± 5.0 (17.9–40.7) 20.9 ± 3.0 (17.6–34.4) < 0.0001
Previous pregnancies (n.; %) 25/33 (75.8%) 11/39 (28.0%) 0.0001
DM Diabetes Mellitus, BMI Body Mass Index
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The mean onset age of disease was 14.7 ± 8.0 years.
The mean duration of disease was 24.9 ± 8.0 years. In
32/33 subjects (97.0%), the duration of DM was longer
than 10 years. No significant correlations were found be-
tween the duration of disease and the total score for the
FSFI-6 questionnaire.
The mean HbA1C of diabetic patients was 7.9 ± 1.4%
(62.7 ± 15 mmol/mol). No statistically significant correla-
tions were found between HbA1c values and total score
for the FSFI-6 questionnaire.
FSD and MDI, CSII
The results are summarized in Table 5a. Among the 33
women with Type 1 DM, 13 (39.4%) were treated with
MDI, while 20 subjects (60.6%) with CSII.
The prevalence of FSD was 30.0% in the CSII group
and 38.5% in MDI-treated women (p =NS).
The comparison of the MDI-treated group, the CSII-
treated group and the control group by Kruskal Wallis
test showed a significant difference for the total score,
and items 1, 2 and 3 (p = 0.0004, p < 0.0001, p = 0.0087
and p = 0.0014, respectively).
Dunn’s post hoc test revealed a significant difference
between the MDI group and the control group (p < 0.01)
and between the CSII group and controls (p < 0.05)
Table 2 Total score and single items score of FSFI-6 in Type 1
DM group and in Control group
Questionnaires Type 1 DM (n.33) Control group (n.39) P value
Total score 20.3 ± 5.3 24.8 ± 3.4 < 0.0001
ITEM - 1 3.1 ± 0.8 4.1 ± 0.7 < 0.0001
ITEM - 2 3.6 ± 1.0 4.1 ± 0.9 0.0156
ITEM - 3 3.2 ± 1.6 4.5 ± 0.8 0.0017
ITEM - 4 3.4 ± 1.4 4.2 ± 0.9 0.0119
ITEM - 5 3.7 ± 1.3 4.2 ± 0.7 0.1119
ITEM - 6 3.3 ± 1.0 3.6 ± 1.0 0.2060
DM Diabetes Mellitus, FSFI Female Sexual Function Index
Table 3 Total score and single items of FSFI-6 in uniparous/
multiparous women and nulliparous women in: a) Type 1 DM
Group; b) Control group
Questionnaires Uniparous/multiparous
Type 1 DM
Nulliparous
Type 1 DM
P value
Total score 20.9 ± 5.4 18.8 ± 5.2 0.3241
ITEM - 1 3.0 ± 0.8 3.1 ± 1.0 0.5540
ITEM - 2 3.6 ± 1.0 3.4 ± 1.0 0.4999
ITEM - 3 3.4 ± 1.6 2.6 ± 1.7 0.2267
ITEM - 4 3.6 ± 1.4 3.0 ± 1.4 0.2557
ITEM - 5 3.7 ± 1.3 3.6 ± 1.3 0.7841
ITEM - 6 3.3 ± 1.0 3.5 ± 0.5 0.5127
Questionnaires Uniparous/multiparous
Control group
Nulliparous
Control group
P value
Total score 25.3 ± 2.4 24.7 ± 3.6 0.9708
ITEM - 1 3.9 ± 0.7 4.2 ± 0.7 0.3551
ITEM - 2 4.6 ± 0.5 4.0 ± 1.0 0.1291
ITEM - 3 4.4 ± 0.8 4.5 ± 0.8 0.7234
ITEM - 4 4.4 ± 0.8 4.2 ± 0.9 0.5296
ITEM - 5 4.3 ± 0.5 4.2 ± 0.8 0.9852
ITEM - 6 3.7 ± 0.8 3.6 ± 1.0 0.8827
DM Diabetes Mellitus, FSFI Female Sexual Function Index
Table 4 Onset and duration of DM, HbA1c values and
parameters of the metabolic syndrome
Mean ± SD (range)
Onset of DM (Age) 14.7 ± 8.0 (2–29)
Duration of DM (Years) 24.8 ± 8.0 (4–40)
HbA1C (%) 7.9 ± 1.4 (5.1–11.7)
HbA1C (mmol/mol) 62.7 ± 15 (32–104)
Total cholesterol (mg/dl) 177.4 ± 25.3 (134–229)
HDL (mg/dl) 56.5 ± 16.9 (31–91)
Triglycerides (mg/dl) 60.5 ± 30.4 (30–194)
LDL (mg/dl) 100.5 ± 18.6 (72.2–149.6)
Blood Pressure Max (mmHg) 116.1 ± 15.0 (100–160)
Blood Pressure Min (mmHg) 70.8 ± 6.5 (60–90)
DM Diabetes Mellitus
Table 5 Total score and single items of FSFI-6 in:: a) CSII and
MDI-treated women vs Control group; b) in women affected by
complicated DM (Complications) or without complications (No
complications) vs Control group
Questionnaires CSII MDI Control
group
P value
Total score 21.5 ± 4.2 18.8 ± 6.6 24.8 ± 3.4 0.0004
ITEM - 1 3.2 ± 0.7 2.9 ± 1.0 4.1 ± 0.7 < 0.0001
ITEM - 2 3.9 ± 0.7 3.2 ± 1.1 4.1 ± 0.9 0.0087
ITEM - 3 3.7 ± 1.4 2.6 ± 1.9 4.5 ± 0.8 0.0014
ITEM - 4 3.5 ± 1.4 3.5 ± 1.5 4.2 ± 0.9 0.1255
ITEM - 5 4.1 ± 0.7 3.1 ± 1.7 4.2 ± 0.7 0.1345
ITEM - 6 3.2 ± 1.0 3.6 ± 1.0 3.6 ± 1.0 0.2386
Questionnaires Complications No
complications
Control
group
P value
Total score 18.1 ± 5.9 22.1 ± 4.1 24.8 ± 3.4 < 0.0001
ITEM - 1 2.9 ± 1.0 3.2 ± 0.6 4.1 ± 0.7 < 0.0001
ITEM - 2 3.3 ± 1.1 3.8 ± 0.8 4.1 ± 0.9 < 0.0133
ITEM - 3 2.5 ± 1.6 3.9 ± 1.4 4.5 ± 0.8 < 0.0002
ITEM - 4 3.1 ± 1.5 3.6 ± 1.3 4.2 ± 0.9 < 0.0257
ITEM - 5 3.1 ± 1.5 4.2 ± 0.8 4.2 ± 0.7 < 0.0296
ITEM - 6 3.2 ± 0.9 3.4 ± 1.0 3.6 ± 1.0 0.2458
DM Diabetes Mellitus, MDI Multi Daily Infusion, CSII Continuous Subcutaneous
Insulin Infusion, FSFI Female Sexual Function Index
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concerning total score, CSII and controls (p < 0.001) and
MDI and controls (p < 0.001) concerning item1, and
MDI and controls for items 2 and 3 (p < 0.01).
Complications of diabetes
Among the 33 women included, 15 (45.5%) showed at
least one DM1 complication between neuropathy (n = 9/
15; 60.0%), retinopathy (n = 10/15; 66.7%), nephropathy
(n = 4/15; 26.7%) and vasculopathy (n = 2; 13.3%).
The results are summarised in Table 5b.
FSD prevalence was 46.6% in the group of women af-
fected by complicated diabetes mellitus compared to
27.8% in the group of women with diabetes mellitus
without complications (p =NS). The comparison of the
three groups (complicated DM, not complicated and
controls) with the Kruskal Wallis test showed a signifi-
cant difference for the total score and for items 1, 2, 3, 4
and 5 (p < 0.0001, p < 0.0001, p < 0.0133, p < 0.0002, p <
0.0257 and p < 0.0296, respectively).
Dunn’s post hoc test revealed significant differences
between: the group with complications and controls for
the total score (p < 0.001), item 1 (p < 0.001), item 2 (p <
0.05), item 3 (p < 0.001), item 4 (p < 0.05) and item 5
(p < 0.05); the group of diabetic women without compli-
cations and controls for item 1 (p < 0.001) and the
groups of women with complicated diabetes and non-
complicated diabetes (p < 0.05).
Discussion
The present study aimed to investigate the association
between type 1 diabetes mellitus and female sexuality. In
recent years, many studies have been carried out regard-
ing FSD [4, 18, 19]; however, as suggested by the meta-
analysis of Pontiroli et al. [12], few and inconsistent data
about FSD in women affected by Type 1 DM are cur-
rently available. Possible explanations for the lack of
strong scientific evidence about this topic could be
found in the absence of standardisation regarding several
studies. Other biases could be represented by small pop-
ulations, age and BMI variability [20], endocrine disor-
ders [21, 22] and concomitant therapies [23].
According to our previous study [17] and that of
Doruk et al. [24], the Type1 diabetic women showed a
significantly higher prevalence of FSD compared to the
control group. In particular, statistical analysis showed
significant differences for total score, item 1 (sexual de-
sire), item 2 (excitation), item 3 (lubrication) and item 4
(frequency of orgasm). No significant differences were
found among the sphere of global sexual satisfaction
(item 5) and dyspareunia (item 6), even though the mean
scores were higher in the control group.
This could be because Type 1 DM is a chronic disease
with a negative impact on the QoL [25] which can affect
sexual function, representing one of the major components
in the QoL of a fertile woman. There are both psychological
and organic causes. Regarding psychological aspects, an as-
sociation between type 1 DM and anxiety-depressive syn-
dromes has been described [11, 26], while organic aspects
include hormonal changes [21, 22], a greater risk of genito-
urinary urinary tract infections [27, 28], the neurotoxic ef-
fect of hyperglycaemia and mucous dehydration (resulting
in vaginal dryness) associated with DM [29].
Several authors showed a higher risk of FSD in women
with a higher BMI [12, 20, 30]. To this regard, some
pathogenic hypothesis have been proposed. Firstly, hor-
monal and inflammatory responses induced by the fatty
cell-secreted cytokine factors (i.e. TNF-alpha, IL-6and
leptin) may contribute to the onset of sexual dysfunction
[31]. Furthermore, an increased BMI could determine
physical impairment and psychological disorders affect-
ing the quality of sexual life, which is strongly related to
the perception of body image [32].
In our study, we highlighted a significant correlation
between BMI values and total score of the FSFI-6 ques-
tionnaire considering overall diabetic and healthy
women. However, when we subdivided diabetic patients
according to BMI values, we did not find any significant
difference in FSFI-6 total scores (mean ± SD) between
the three groups; this finding could depend on the small
number of obese women with a moderate/severe obesity
of our study group. Furthermore, a logistic regression
analysis performed using FSD as dependent variable and
BMI and diabetes as different predictors, only diabetes
remained significant. Considering these results, type1
DM seems to be the main risk factor for FSD in young
fertile women.
Regarding the type of insulin administration, we ob-
served a higher prevalence of FSD in women with MDI
administration compared to CSII, both for total score
and single items, showing better sexual outcomes in the
second group, even though the results are not statisti-
cally significant. These results are in agreement to those
of Maiorino et al. [4], showing that women with type 1
DM and CSII therapy have a lower prevalence of FSD
than women undergoing MDI therapy. This could be
due a reduced variability of the glycaemic profile in pa-
tients with CSII compared to MDI, as suggested by
Reddy et al. [33].
The CSII group showed a prevalence of FSD similar to
that of the healthy population.
Regarding the possible relationship with diabetes com-
plications, according to previous studies [26], we ob-
served a higher prevalence of FSD in women with
complicated diabetes compared to uncomplicated dia-
betes. As pathogenic factors, diabetic neuropathy (mostly
the sensory component) could affect genital sexual re-
sponse to tactile stimulation [34], while diabetic angio-
pathy could lead to hypotrophy of clitoral erectile
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structures (resulting in a reduced response to sexual
stimulation) and a reduction or lack of vaginal lubrica-
tion (with greater risk of dyspareunia) [7].
To this regard, recent studies highlighted that the
peripheral sexual response in female is a vascular-
dependent event and the vascular function of the
genital tract could be affected by common cardiomet-
abolic alterations [35, 36].
It is not surprising that item 3, vaginal lubrication, was
the one which showed the greatest differences within the
study sample: not only between diabetic women and
controls, but also between women with complicated and
uncomplicated DM. Other complications, such as ne-
phropathy [37], retinopathy, foot ulcers [38, 39] and
autonomic heart disease [40, 41], may also have a nega-
tive effect on the overall quality of life and, indirectly, on
sexual activity.
One of the most important studies about this aspect
was by Enzlin et al. [26], which referred to a large cohort
study on FSD in type 1 diabetic women. The author
highlighted a significant association between FSD and
diabetic microangiopathy.
Despite there is evidence that nulliparous women
show superior sexual function scores compared with
parous women [42], we did not find any association be-
tween parity and FSFI-6 scores inside each single study
group. This could be due to the small number and to
the differences in the prevalence of uniparous/multipar-
ous women between the study group and the control
group. Moreover, we explored FSFI in young women
after more than 1 year from their last pregnancy.
Finally, the assessment of female sexual function only by
using a questionnaire and the lack of hormonal parame-
ters and clitoral ecolorDoppler ultrasound of the study
population represented the limits of this study. Future and
larger studies on hormonal, clinical and instrumental as-
pects as well as on psycho-relational components will help
in understanding the role of these factors on sexual func-
tion of fertile women with type1 diabetes.
Conclusions
In conclusion, this study underlined that FSD is higher
in women affected by type 1 DM than in healthy con-
trols. This could be due to the diabetic neuropathy/
angiopathy and the type of insulin administration.
Therefore, it should be very important to investigate
FSD in diabetic women, as well as erectile dysfunction in
diabetic males.
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